Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 March;64(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 March;64(1):131-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 March;64(1):131-8

DOI: 10.23736/S1824-4785.18.03031-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site

Mathieu GAUTHÉ 1, 2 , Matthieu BRETON 1, Nina JEHANNO 1, Cécile CELLIER 3, Jean MICHON 4, Sabine SARNACKI 5, Gudrun SCHLEIERMACHER 3, Myriam WARTSKI 1

1 Unit of Nuclear Medicine, Curie Institute, Paris, France; 2 Unit of Nuclear Medicine, Tenon Hospital, AP-HP, Paris, France; 3 Unit of Radiology, Curie Institute, Paris, France; 4 Unit of Pediatrics, Curie Institute, Paris, France; 5 Unit of Pediatric Surgery, Necker Hospital, Paris, France



BACKGROUND: The aim of this study was to assess the prognostic value of postoperative 123I-MIBG scintigraphy, including systematic SPECT/CT and semiquantification of the uptake at the surgical site, in a prospective series of NB patients.
METHODS: Patients operated for neuroblastoma and who had benefited from postoperative 123I-MIBG scintigraphy were prospectively and consecutively included. Completeness of surgery was assessed on operative report. One month postoperative 123I-MIBG scintigraphy included planar acquisition and SPECT/CT. Semi-quantification of the 123I-MIBG SPECT/CT uptake at the surgical site was performed and ratios to reference (liver and mediastinum) areas were calculated.
RESULTS: Thirty patients were included between August 2012 and July 2015. Median follow-up was 36 months (range 10-98). Surgery was considered as complete in 23 patients and incomplete in 7 patients. Eight patients (26.7%) presented progressive disease (1 progression and 7 recurrences). Seven patients died (23.3%), all from NB. Six (20%) patients had positive 123I-MIBG scintigraphy (3 on planar acquisitions and 6 on SPECT/CT) and 24 patients had negative 123I-MIBG scintigraphy. Five of the 6 patients (83%) with positive 123I-MIBG scintigraphy presented progressive disease. Ratio of the uptake at the surgical site to mediastinum was strongly and independently correlated with disease-free interval and overall survival (P=0.02 and 0.01 respectively). The amplified MYCN status was also confirmed as correlated with poorer outcomes.
CONCLUSIONS: Postoperative 123I-MIBG scintigraphy including SPECT/CT and semiquantification of the uptake at the surgical site appeared to be a valuable prognostic tool in neuroblastoma.


KEY WORDS: Neuroblastoma; Pediatrics; Survival

top of page